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Down syndrome (DS) is a condition where a complete or segmental chromosome 21 trisomy causes variable intellectual disability,
and progressive memory loss and neurodegeneration with age. Many research groups have examined development of the brain in
DS individuals, but studies on age-related changes should also be considered, with the increased lifespan observed in DS. DS leads
topathologicalhallmarksofAlzheimer’sdisease(AD)by40or50yearsofage.Progressiveage-relatedmemorydeﬁcitsoccurringin
bothADandinDShavebeenconnectedtodegenerationofseveralneuronalpopulations,butmechanismsarenotfullyelucidated.
Inﬂammation and oxidative stress are early events in DS pathology, and focusing on these pathways may lead to development of
successful intervention strategies for AD associated with DS. Here we discuss recent ﬁndings and potential treatment avenues
regarding development of AD neuropathology and memory loss in DS.
1.Introduction
The most common cause of dementia is Alzheimer’s disease
(AD), with rates of prevalence increasing steadily from 60
years of age to reach almost 40% by the age of 85 [1].
AD is deﬁned as the presence of neuritic plaques, which
are composed of extracellular deposits of amyloid beta, and
neuroﬁbrillary tangles [2]. Neurodegeneration in the later
stages of AD is widespread, with massive synapse loss and
an overall decline in grey matter resulting from neuronal
loss in cortical and hippocampal regions. Cortical neuronal
loss is preceded by degeneration of certain subcortical
neuronal populations, including basal forebrain cholinergic
neurons(BFCNs)[3]andnoradrenergicneuronsofthelocus
coeruleus (LC-NE) [4, 5].
While the majority of AD cases are considered sporadic,
mutations in amyloid precursor protein (APP) and prese-
nilins 1 and 2 (PS-1 and PS-2) genes are responsible for
most of the cases of AD considered “familial” [6]. These
mutations lead to alterations in APP metabolism that result
in an overabundance of amyloid plaques. Similarly, APP
processing is also aﬀe c t e di nD o w ns y n d r o m e( D S ) ,ap o p u -
lation who exhibit histopathology consistent with AD by the
4th and 5th decades of life with near uniformity, as well as
increased risk for dementia [7, 8]. Located on chromosome
21, APP is triplicated in DS, and amyloid-beta deposition
is frequently profound in these individuals [9–11]. Recently,
cases of familial AD resulting from duplication of only the
APP locus have been discovered [12], further deﬁning a
role for APP in AD dementia. However, few studies have
been able to correlate plaque load with dementia severity.
Rather, cognitive function correlates most strongly with the
degeneration of cholinergic neurons in the basal forebrain.
Reversal of cholinergic hypofunction in AD with choline
acetyl transferase inhibitors has been shown to facilitate
memoryfunction,albeittoamoderatedegree[13].However,
itisstillnotknownwhatcausesthecholinergicdegeneration,
orifotherparallelfactorsalsocontributetothedisease.Some
potential mechanisms include neuroinﬂammation, oxidative
stress, amyloid toxicity, and abnormal phosphorylation of
proteins including the microﬁlament-associated protein tau;
etiological causes include genetic mutations, diet, sedentary2 Current Gerontology and Geriatrics Research
lifestyle, and environmental toxins [14]. While familial
causes of AD are rare and idiopathic AD is diﬃcult to model,
DS presents a large and relatively homogenous population
with relevant animal models that can serve to illuminate
possible etiologies or treatment paradigms in AD.
In the current paper, we will discuss current theories
regarding biological mechanisms and potential treatment
paradigms for DS individuals with AD-like dementia (DSD).
Weincludedatafromanimalmodels,aswellasfromhumans
withDSD,andproposepotentialearlypreventionmodelsfor
this diﬃcult and progressive condition.
2.Down Syndrome:AGeneticInsightintoAD
The uniformity with which individuals with DS acquire AD
neuropathology makes this population important to study,
not only to gain a better understanding of AD, but also
because there are currently no eﬀective treatment paradigms
for DSD [8, 15]. Because they have physiological alterations
in cardiac and metabolic systems, cholinesterase inhibitors
may be contraindicated in some DSD patients [15, 16]. DS
is the most common aneuploidy, occurring as frequently as
approximately 1 in every 700 live births in the US [17]. DS
results in variable levels of intellectual disability, along with
congenital defects, and increased risk of certain cancers, such
as leukemias [18]. As maternal age continues to increase
and medical interventions have increased the lifespan of DS
individuals, the prevalence of DSD continues to grow. The
diverse and heterogeneous neurodegeneration in AD and
in normal aging are accelerated in DS, and lessons learned
from DSD patients may uncover therapeutic targets with
widespread implications. In fact, DS can be considered a
form of segmental progeroid syndrome, or accelerated aging
[19, 20].
Studies assessing the eﬀects of age on cognition in DS
demonstrate a greater incidence of short-term memory
impairment in DS individuals over 35 years of age, as well
as increasing rates of dementia, aphasia, and agnosia [23]
while detriments in executive function are evident already in
adolescence [24]. As in idiopathic AD, DSD patients display
dysfunction of language and motor skills, seizure onset,
and behavioral abnormalities [25], in addition to AD-like
pathology, including amyloid-beta deposits, neuroﬁbrillary
tangles, loss of BFCNs, and pathological alterations in
mitochondria and endosomes [26–29]. While trisomy 21
constitutes the triplication of over 300 genes [30, 31], recent
animal studies have sought to elucidate which genes may
contribute to the observed neurodegenerative pathology.
Based on genetic studies in mouse models of DS, several spe-
ciﬁc genes contained within the triplicated region of murine
chromosome 16 (which corresponds to an equivalent section
on human Chr. 21; see Figure 1) have been implicated in
the DSD neuropathology. One of the most important genes
associated with DS is the amyloid precursor protein (APP)
gene—increased APP production may partially contribute to
DSD-related oxidative stress as well as inﬂammation. Accu-
mulation of amyloid-beta monomers can directly impair
mitochondrial function resulting in energy depletion [32],
and it is also well known that accumulation of amyloid—
either in tissue culture or in vivo—leads to activation
of inﬂammatory cascades [33, 34], most likely via both
microvascular dysfunction and activation of resident glial
cells in brain parenchyma. Furthermore, cortical DS neurons
exhibit impaired mitochondrial function that results in
reduced energy production and elevations in reactive oxygen
species (ROS) [35]. Studies using the Ts1Cje mouse model
for DS, which does not include triplication of the SOD or
APP genes [36], suggest that other triplicated genes may be
involved in mitochondrial abnormalities observed in DS. In
addition, while APP and SOD-1 each may contribute to the
disease,neithergeneissolelyresponsibleforthedegenerative
changes that occur in DS [37]. Other genes located on the
critical region include Ets-2 and DSCR1 (Figure 1), which
have both been linked to neurodegeneration [35, 38]. In this
paper, we will provide evidence, from our recent work and
others, suggesting that inﬂammation and oxidative stress are
earlydysregulationswhichmayberesponsibleforage-related
dementia and associated pathology in DSD.
3.Modeling DSPathology: The Ts65Dn Mouse
As discussed elsewhere in this issue, a spontaneous translo-
cation of a portion of murine chromosome 16 onto chro-
mosome 17led to the formation of a DS model, the Ts65Dn
mouse [39]. The translocated segment of chromosome 16,
syntenic to a signiﬁcant portion of human chromosome 21
(Figure 1), thus provided a genetic triplication which can
be passed on to oﬀspring [39]. Nearly 140 known genes
are triplicated in Ts65Dn mice, of which 60% are also
located on human chromosome 21 [40]. More importantly,
these mice exhibit normal lifespans, allowing for the analysis
of progressive neurodegenerative alterations. While Ts65Dn
micefailtodevelopamyloidplaques,theydoexhibitelevated
levels of APP and associated peptides in the hippocam-
pus [41–43] and increased phosphorylation of tau protein
[44, 45]. Ts65Dn mice also show increased inﬂammatory
morphology with aging [22, 46] (see also Figure 2)s y n a p t i c
dysfunction [47, 48], and a failure of neurotrophic signaling,
particularly involving the retrograde transport of nerve
growth factor (NGF) to the basal forebrain [42, 46, 49, 50],
and downregulation of brain-derived neurotrophic growth
factor (BDNF) levels [51, 52]. In addition, they exhibit age-
related degeneration of LC-NE and BFCN neurons [22, 53–
55]. Memory deﬁcits are progressive in these mice and onset
coincides with BFCN atrophy [43, 46, 56]. Interestingly, a
study by Belichenko et al. [57] suggested that 33 genes,
included in the so-called “DS critical region” (DSCR) of
genes in humans, and triplicated in a novel mouse model
(Ts1Rhr), might be responsible for many of the physiological
and behavioral detriments observed in the Ts65Dn mice,
narrowing the search for the set of genes involved in DSD
neuropathology [57]. However, other studies have shown
that although this “critical region” is necessary for cognitive
impairment and pathology to develop [58], overexpression
of these particular genes is not suﬃcient to generate DSD,
at least not in mouse models, demonstrating the complexCurrent Gerontology and Geriatrics Research 3
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Figure 1: Mouse models for DS. Schematic of the gene segments involved in the so-called “Down syndrome critical region” (DSCR) in
human chromosome 21, as well as in diﬀerent mouse models of the condition. Note that the Ts65Dn mouse contains all genes included in
the DSCR, as well as a set of 132 other genes including SOD and APP. Modiﬁed from Antonarakis et al. 2004 [21].
nature of DS-related dementia and neuropathology with
aging.
While degeneration of basal forebrain cholinergic neu-
rons (BFCNs) occurs during normal aging, DSD and AD are
deﬁned by rapidly accelerated loss of these projection neu-
rons, and cholinergic dysfunction correlates strongly with
the progression of cognitive decline in both diseases [59, 60].
Ts65Dn mice show consistent learning and memory deﬁcits
on spatial reference and working memory tasks [56, 61–67].
Most of these deﬁcits become apparent between 4 and 12
months of age [56], suggesting, indeed, that the behavioral
dysfunction developing in the Ts65Dn mouse mimics the
segmental progeria syndrome observed in terms of brain
function in humans with DS. Ts65Dn mice exhibit deﬁcits
in novel object tasks, which are reversed by the partial N-
Methyl-D-aspartic acid (NMDA) glutamate receptor blocker
Memantine (Namenda) [68–70]. These ﬁndings suggest that
glutamate and GABA transmitter systems are aﬀected by
the genetic alterations in Ts65Dn, directly or indirectly,
in Ts65Dn mice, something that has been suggested by
work from other research groups as well [71, 72]. In a
manuscript by Rueda et al. [71], they found that treatment
with memantine in aged Ts65Dn mice improved spatial
learning but did not aﬀect the number of dentate granule
cells, suggesting that the eﬀects of memantine may be
pharmacological, rather than neuroprotective. These data
were further supported by our ﬁndings, that memantine
increased working memory performance, particularly in4 Current Gerontology and Geriatrics Research
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Figure 2: Gliosis in hippocampus of Ts65Dn mice. Brain tissue sections from Ts65Dn mice and age-matched normosomic littermates,
showing typical hippocampal morphology of astrocytes, using the glial marker GFAP (a) and (b). The sections were from 12-month-old
normosomic (NS, a) or Ts65Dn (TS, b) mice. Note increased number of astrocytes in TS mice, as well as elevated expression of GFAP and an
activated morphology, with more branching and thicker branches in the TS compared to NS mouse. (c) Astrocyte branching measurements
(GFAP labeling) in the hippocampus reveal increased branching in TS mice compared to NS age-matched controls, a sign of activation
following inﬂammatory or other pathological processes. Astrocytosis is increased with aging in the TS mice to a greater extent than in NS
mice. (d) Density of a marker for microglial cells, Cd45, is also increased with age in Ts65Dn (TS) but not in age-matched normosomic (NS)
mice, indicating ongoing microglial activation in this brain region. Inset in (b) represent 100 microns. Data were not published previously.
a novel object task, but did not rescue hippocampal, cholin-
ergic, or locus coeruleus neurons from progressive neu-
rodegeneration [70]. The cognitive impairment observed
over time in Ts65Dn mice parallels cognitive impairment
in adult DS individuals with early or moderate AD, tested
on the WISC-R behavioral battery, showing progressive
deterioration in executive function, comprehension, picture
completion, vocabulary, and digit span [73]. The memory
deﬁcits indicate hippocampal and frontal cortex dysfunction
and together with septohippocampal degeneration indicate
that the Ts65Dn mouse is a unique model to understand the
progression of neuropathology and memory loss in DSD.
4.LocusCoeruleus Degeneration inDSD
LC-NE degeneration, while less studied than BFCN loss, is
another hallmark of AD [74]. NE neurotransmission exerts
eﬀects on neurons, glia, and blood vessels throughout the
neuraxis. LC-NE lesions, using the selective NE neuro-
toxin DSP-4, give rise to aggravated amyloid accumulation,
oxidative stress, and memory loss in transgenic AD models
[75–77]. Findings suggest that LC-NE eﬀects are mediated
both directly, via neurotransmission changes in the limbic
system, and indirectly, via aggravation of amyloid accumu-
lation, inﬂammation, and oxidative stress pathways. NE-
mediated neuroprotection of oxidative stress on BCFNs in
vitro is independent of adrenergic receptor activation or
intracellular accumulation, [78] suggesting a role for NE in
the neutralization of hydroxyl radicals. The antioxidant
activity of NE provides a pharmacological link between
LC-NE and cholinergic survival. NE circuitry also exhibits
a direct inﬂuence on memory formation. BFCNs activity
is modulated by NE via adrenergic receptor activity [79],Current Gerontology and Geriatrics Research 5
and pharmacological stimulation of NE receptors leads to
improved cognitive performance both in rodent models and
in humans [80]. While NE is an essential modulator of
memory through its ability to regulate synaptic mechanisms,
NE depletion is not suﬃcient to signiﬁcantly alter memory
function in intact animals [22]. Yet, NE depletion in the
presence of cholinergic dysfunction exacerbates memory
impairments [22] and may therefore aggravate deﬁcits in
memory systems dependent on the basal forebrain cholin-
ergic neurons. In a recent study, Ts65Dn and NS mice
were lesioned using the NE neurotoxin DSP-4 at 4 months
of age and were then studied at 8–10 months of age in
terms of behavior and neurochemistry. As can be seen in
Figure 3 and in [22], the NE lesion gave rise to a signiﬁcant
aggravation of both memory loss and neuropathology in
Ts65Dn but not in NS mice, including degeneration of
hippocampal and BFCNs as well as increased inﬂammatory
markers. These ﬁndings suggest that NE neurotransmission,
albeit important for normal function of the brain, plays a
particularlyimportantroleforcurbingage-relatedpathology
in the form of inﬂammation and neuronal loss. This notion
hasbeensupportedbyotherinvestigators,showingenhanced
eﬀects of DSP-4 lesions in APP transgenic mice [76, 81, 82].
These investigators also found that administration of the
NE precursor L-threo-DOPS restored microglial functions
in NE-depleted mice [76], suggesting a reciprocal system
where the amyloid cascade, inﬂammatory markers, and NE
innervation systems aﬀect each other. Interestingly, others
have also shown that LC neurons spontaneously degenerate
in AD mouse models [83], again suggesting a speciﬁc link
betweenacceleratedamyloidaccumulationanddegeneration
of LC neurons.
Importantly, individuals with DSD exhibit early and
progressive degeneration of LC-NE neurons [84]. Recently,
a study by Salehi et al. [55] demonstrated successful recovery
from memory loss in Ts65Dn mice using the NE precursor
Droxidopa (L-threo-dihydroxyphenylserine). These results
are promising and should be considered in future clinical
treatment paradigms for DSD patients. Since LC-NE degen-
eration is common to both Parkinson’s disease (PD) and
AD patients [85–87], future pharmaceutical interventions
for dementia may include enhancement of NE neurotrans-
mission also for these neurological conditions. Promising
clinical pilot studies have already been initiated in terms
of the NE reuptake inhibitor Atomoxetine and memory
loss in PD [88] and in Alzheimer’s disease [89, 90]e v e n
though much remains to be done in terms of incorporating
NE enhancement treatment for dementia. LC-NE neurons
partake in the regulation of blood vessels, microglial cells, as
wellasneurons,anddegenerationofthismonoaminergiccell
group can be an active player in neuropathological processes
in age-related dementia of diﬀerent etiology.
5.InﬂammatoryPathology inADandDSD
As in AD, individuals with DSD consistently exhibit chronic
inﬂammation in limbic system areas of the brain, with
increases in microglial and astrocytic activation coupled
with IL-1β and TNF-α cytokine release [91–93]. Microglial
activation typically arises in the entorhinal cortex before
developing in the hippocampus and surrounding cortex
as well as the basal forebrain [26, 27]. BFCNs are highly
sensitive to inﬂammation and oxidative stress [94], but
speciﬁc biological mechanisms for their selective loss in AD
and in DSD have not been revealed. There is also evidence
that TNF-α-induced cortical inﬂammation at cholinergic
terminals leads to retrograde degeneration of BFCNs [95].
Recent work suggests that inﬂammation due to loss of
noradrenergic innervation from the LC-NE innervation of
BFCNs is a plausible explanation for the selective vulnera-
bility of these neurons in DSD and AD [22]. β-adrenergic
receptors are expressed in astrocytes and microglia and
modulate the cytokine release [96]. The reduction of nora-
drenergic neurons in the LC correlates with amyloid plaques
and dementia severity in AD [97, 98]. NE treatment of
cholinergic cells in vitro reduces expression of IL-1β and
TNF-α, as well as proinﬂammatory proteins such as iNOS
[96]. Since Ts65Dn mice exhibit signiﬁcant degeneration
of both BFCNs and LC-NE neurons, it is not surprising
that we found accelerated and age-related astrocytosis and
microgliosis in the hippocampus of this mouse model of
DS (Figures 2 and 3). As mentioned above, depletion of
noradrenergic terminals in murine models of AD results
in increased inﬂammatory cytokine production, activated
microglial morphology, and amyloid deposition [76, 82,
99]. NE terminal destruction also impeded cholinergic
neurotransmission in AD models which otherwise show
no cholinergic deﬁcits [81]. Thus, while inﬂammation may
aﬀect many of these neurodegenerative processes, it also can
increase in response to early abnormalities in ACh and NE
signaling, since there is a reciprocal relationship between
neuronal and glial modulation of inﬂammatory processes,
especially during neurodegenerative disease [96]. Based on
these studies, it is diﬃcult to determine whether BFCN and
LC-NE degeneration activates the inﬂammatory pathways,
or if the cytokine production by astrocytes and microglia, in
turn,causestheneuronaldegenerationinDSDandAD.Most
likely, all of these processes have interactive and escalating
eﬀects on each other, leading, in the end, to memory loss and
AD pathology.
6. Neurotrophic FactorsandDS
The survival and maintenance of BFCNs depend on
neurotrophic support from NGF and BDNF [100]. NGF
mRNA is expressed at high levels in regions innervated by
cholinergic terminals, such as the neocortex, dentate gyrus,
and the hippocampal pyramidal layer [3]. Upon release
from postsynaptic neurons, NGF binds to its high-aﬃnity
receptor, TrkA, on BFCN nerve terminals, initiating receptor
oligomerization which leads to signaling cascades through
PI3K and ERK activation and endocytosis of the ligand-
receptor complex [101]. This complex is retrogradely trans-
ported to the soma where it facilitates signal transduction of
p h e n o t y p i cm a r k e r ss u c ha sc h o l i n ea c e t y l t r a n s f e r a s e[ 101,
102].ExogenousadministrationofNGFrescuesBFCNsfrom
age- or toxin-related degeneration and reverses cognitive
dysfunction in animal models of AD or normal aging [103].6 Current Gerontology and Geriatrics Research
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Figure 3: Eﬀects of the NE neurotoxin DSP-4 on Ts65Dn and normosomic mice. Note signiﬁcant aggravation of performance in a
memory task (a) coupled with aggravated activation of microglial cells (b–d) in the hippocampal formation, as evidenced by Cd45
immunohistochemistry. (a) Average number of errors in a water radial arm maze. The NE lesion exhibited more pronounced eﬀects on
errors in the maze in TS than in NS mice, and TS mice performed more errors than NS mice, regardless of NE lesions (DSP) or not (Sal).
(b–d) Cd45 staining of microglial cells in the hippocampus in a normosomic mouse (NS) treated with saline (b), a Ts65Dn mice on saline
(c), and a Ts65Dn mouse that received DSP-4 lesions of the LC-NE neurons (d). Note signiﬁcant activation of individual microglial cells as
a result of the NE lesion in TS mice compared to controls. Quantitation of inﬂammatory processes is available in Lockrow et al., 2011 [22].
While the production of NGF in the hippocampus and
cerebral cortex has been shown to be unaltered or even
increased in AD [103], NGF levels in the basal forebrain
exhibit signiﬁcant decline [104]. A compensatory increase
in NGF expression in target regions may be due in part to
loss of TrkA receptor expression in BFCN neurons, which
occurs early in AD and is recapitulated in aged rodents [3,
105]. Murine models for DS show reductions in retrograde
NGF traﬃcking which occurs in part due to enlarged,
dysfunctional endosomes [42, 49, 101]. Recent studies have
shown that these endosomal changes can be caused by
overexpression of APP [42, 106]. Abnormal endosomes are
present in both AD and DSD brains [29] and localize to
the vulnerable regions such as the basal forebrain and the
hippocampus [107] suggesting that endosomal traﬃcking of
NGFlinkedtoTrkAmaybeapathologicalpathwaytoexplore
further in DSD brains.
BDNF also promotes BFCN survival and cholinergic sig-
naling [108–110]. BDNF expression is reduced in AD [109],
and BDNF levels are reduced in serum from DS individuals
[111], and in brain tissue from the Ts65Dn mouse model
for DS [52], and has been shown to be linked to memory
function, as well as synaptic plasticity and neurogenesis
[112]. BDNF expression is increased following exercise and
maythereforecontributetothebeneﬁcialeﬀectsofvoluntary
exerciseobservedinADaswellasinnormalaginginhumans
and animal models [113–117]. Interestingly, several studies
have shown that LC-NE innervation into cortical regions
regulates the expression of BDNF, suggesting a close link
between loss of BDNF expression and LC-NE degeneration
in DS [118]. In a recent manuscript by Counts and Mufson
[119], the authors demonstrated that administration of
NE protected cultured neurons from amyloid-beta-mediated
toxicity by upregulating both NGF and BDNF expression.
Further, the authors found that NE inhibited increased
reactive oxygen species (ROS) and caspase activation caused
by the neurotoxin, suggesting also a direct link between the
neurotrophic factors, NE innervation, and oxidative stress.Current Gerontology and Geriatrics Research 7
Treatment with functional blocking agents for NGF and
BDNF removed the beneﬁcial eﬀects, indeed suggesting that
NE eﬀects were mediated by the trophic factors. This paper
therefore linked several pathological processes in DSD and
AD, providing direction for future research and treatment
options. Our recent study using Ts65Dn mice extended these
ﬁndings in vivo, by showing that an LC-NE lesion, using
the neurotoxin DSP-4, decreased BDNF expression in frontal
cortex, a region associated with working memory loss in
the Ts65Dn mouse model [22]. We also found a signiﬁcant
correlation between BDNF expression and NE levels, as
well as between BDNF expression and working memory
errors, suggesting a clear link between BDNF expression and
memory function dependent on this region. BDNF and NGF
have been associated with neuroprotection against oxidative
stress in neurons [119, 120], suggesting that DSD patients
may exhibit increased sensitivity to oxidative stress because
of reduced expression of these neurotrophic factors.
7.OxidativeStressand DSDPathology
Individuals with DS exhibit elevated oxidative stress early in
life [121]. Oxidizing free radicals, also known as ROS, are
cytotoxic byproducts of normal mitochondrial metabolism
and are normally processed by endogenous antioxidants.
But when levels of mitochondrial ROS production exceed
the intracellular antioxidant defenses, oxidative molecules
can disrupt cellular functions, negatively aﬀecting synaptic
plasticity and eventually leading to neuronal injury and
apoptosis [122]. The hippocampal formation exhibits a
high vulnerability to both ischemic and neurotoxic injury
associated with oxidative stress [123]. A marker of RNA
oxidative damage, 8-hydroxyguanosine (8-OHG), is elevated
in neurons of the hippocampus and cortex early in the
progression of AD and precedes much of the pathology
in these regions, suggesting that oxidative stress may be
the earliest event in AD-related disease processes [124].
Postmortemanalysisrevealedthat8-OHGimmunoreactivity
increased signiﬁcantly in cortical neurons of DS individuals
in their teens and twenties, while amyloid-beta burden was
increased only after 30 years of age [125], strongly suggesting
that oxidative stress is an early event also in DS. The central
question is why is oxidative stress so rampant in the brain of
DS individuals?
Partoftheanswertothatquestionmaybethetriplication
of both APP and SOD-1 genes in DS (Figure 1). The balance
between ROS production and the scavenger enzyme path-
waysistightlyregulatedinthecellduringnormalconditions.
We propose that the increase in expression of SOD-1 in DS
leads to a reduction in superoxide but an increase in the
accumulation of hydrogen peroxide (H2O2) in tissues. This
hypothesis is based on a superarray using pooled samples
of tissue from the hippocampus of Ts65Dn mice revealing
signiﬁcantelevationsinhippocampalSOD-1expressionwith
only a moderate increase in the other scavenger enzymes,
including glutathione reductase and catalase (Figure 4).
Elevated rates of conversion from superoxide to H2O2 would
lead to lipid peroxidation in neurons and glia, accumulating
with time, and leading to the neuropathology observed in
Ts65Dn mice with age, as well as in DS individuals. This
hypothesis was recently validated by studies from Harris-
Cerruti et al. [37], showing that a mouse model consisting
of double SOD-1/APP overexpression leads to memory
loss and neuropathology, as well as elevated ROS in the
brain, while APP overexpression alone was less eﬀective in
generating neurodegeneration or ROS accumulation. When
the investigators examined hippocampal slices for long-term
potentiation (LTP), they found that LTP was impaired in
bothtg-SODandtg-APP-SODmice,butnotintg-APPmice,
suggesting that the APP overexpression alone did not aﬀect
this cellular component of hippocampal plasticity. SOD-1
overexpression alone also gave rise to ROS accumulation,
but not to the extent observed in APP/SOD-1 overexpression
mice, suggesting a comodulation of oxidative stress pathways
by the APP and SOD-1 genetic overexpression [37].
There is a controversy in the literature regarding beneﬁ-
cial or damaging eﬀects of SOD overexpression. While some
investigators show that SOD-1 or SOD-2 overexpression
rescues neuropathology in AD transgenic mouse models
[126], others demonstrate aggravated pathology when over-
expressing SOD-1 [126], suggesting that there is a com-
plicated relationship between SOD-1 and SOD-2 function
in the CNS. Gardner and colleagues [127]i n v e s t i g a t e d
this question using a minimal mathematical model. The
authors concluded that the outcome depended on a balance
between processes consuming superoxide without forming
H2O2 andthoseconsumingsuperoxidewithhighH2O2 yield
[127]. Our investigations shed some light on this particular
questionforDSbrains,sinceTs65Dnmiceexhibitedelevated
expression of both glutathione and catalase (Figure 4),
presumablyasaresponsetoelevatedH2O2 levelsinthebrain.
However, since most investigators use indirect methods of
measuring H2O2, such as measuring lipid peroxidation or
associated markers, it has not been shown, at least not to
our knowledge, whether neurons or glia from DSD patients
or Ts65Dn mice exhibit elevated H2O2 levels, even though
studies of postmortem brain tissue have shown that levels of
peroxiredoxin, which is an enzyme involved in eliminating
H2O2, are elevated in both DSD and AD [128]. The role
of oxidative stress in development of pathology in DS
individuals is further discussed in other sections of this issue.
Early increases in ROS suggest that antioxidant therapy
may beneﬁt DS individuals with AD pathology. While
clinical results for vitamin E treatment in AD patients
have been mixed to this point [129], there have been
minimal studies to determine whether antioxidants could
be beneﬁcial in DSD, despite a recent study of vitamin E
administration during childhood in DS [130]. We recently
reported beneﬁcial eﬀects of long-term vitamin E treatment
in Ts65Dn mice [131] and suggest that this may be a viable
future option for DSD. Ts65Dn mice were given vitamin
E in their diet from 4–10 months of age, and cognitive
performance was tested, followed by brain pathology. BFCN
and hippocampal cell loss were reduced signiﬁcantly, and
neuroinﬂammationassociatedwithmicroglialactivationwas
also signiﬁcantly reduced, suggesting a strong connection
between inﬂammatory and oxidative stress pathways [131].
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Figure 4:(a)Superarray(SABiosciences,Frederick,MD)againstoxidativestressandinﬂammatorymarkerswasusedonhippocampaltissue
from pooled samples (3 per group) of Ts65Dn and Normosomic mice at 4, 8, 10, and 13 months of age. Note the increased expression in APP
andSOD-1duetoincreasedgenedosageofthesegenes.However,glutathioneperoxidase1and3(GPX1and3),aswellascatalaselevels,were
not increased to the same extent. Further investigation of the glutathione enzymatic pathway revealed increased GSSG:GSH ratio in Ts65Dn
compared to normosomic brain (b), suggesting, a compensatory processing of free radicals, but not suﬃcient to eliminate peroxidation in
neurons. Glutathione exists in two forms: GSH (reduced form) and GSSG (oxidized form). Normally the relationship between these two
forms is 1:10 in healthy cells. (c) Schematic representation of the ROS scavengers, demonstrating that elevated SOD levels may lead to
increased H2O2 levels, leading to enhanced stress on the glutathione and catalase pathways. Data were not published previously.
performance, supporting the hypothesis that oxidative stress
plays an important role for memory loss associated with
DSD. Based on these encouraging ﬁndings, and the relatively
minor risks associated with vitamin E treatment, we would
suggest future development of this treatment paradigm for
individuals with DS as a prevention strategy.
8. Overexpressionof APP: Disease Modiﬁer
An involvement of the amyloid cascade in the progres-
sive memory loss and neuropathology in DS cannot be
denied. It is likely that the overproduction of APP in DS
individuals (Figure 1) converges upon both oxidative stress
and inﬂammation pathways in the brain, to cause added
harm to the DSD patient with time. Amyloid-beta-induced
oxidative stress appears to be mediated through an NMDA
receptor-mediated increase in Ca2+ inﬂux [132]. Elevated
intracellular Ca2+ disrupts mitochondrial function [133]
and may explain the reduced mitochondrial eﬃciency seen
in AD. As previously shown by our laboratory, Ts65Dn
mice have deﬁcits in expression of calbindin, a neuronal
calcium-binding protein, in the hippocampus [46], suggest-
ing further dysregulation of intracellular Ca2+ pathways.
It is also possible that other genetic components of the
triplicated genesegment aggravateDS-relatedADpathology.
The regulator of calcineurin 1 (RCAN1 or DSCR1) is also
over-expressed in DS and in Ts65Dn mice (Figure 1). A
recent manuscript by Porta et al. [134] demonstrated that
RCAN1 knockout neurons (RCAN1−/−) exhibited a reduced
response to oxidative stress, and the investigators therefore
suggested vulnerability to oxidative stress downstream from
the SOD-1-mediated accumulation of H2O2 in DS and in
AD. These ﬁndings are important for continued eﬀorts inCurrent Gerontology and Geriatrics Research 9
determining the role of diﬀerent genes in DS to provide
additional substrates for neuroprotection strategies.
9. OutstandingQuestions
Outstanding questions in this ﬁeld should focus on preven-
tion and/or treatment options for DSD. As individuals with
DS live longer and medical interventions have been able to
modify cardiovascular problems or other health issues, the
incidence of DSD will go up dramatically in the next couple
of decades. Based on recent ﬁndings related to vitamin E and
antioxidant capacity, we feel that it is important to assess
prevention in DS individuals at an early stage using vitamin
E and/or other antioxidants. Further, treatment with NE
enhancing drugs, such as Atomoxetine (Strattera) [88, 135],
has shown promising results in children with ADHD and
in PD; it is possible that these pharmaceutical interventions
may be beneﬁcial for working memory deﬁcits and early
onset problems with executive function in persons with DSD
as well. It is important to note that several disease processes,
related to inﬂammation, oxidative stress, cholinergic cell
loss, calcium homeostasis, amyloid accumulation, and locus
coeruleus degeneration, all converge on the progressive
deﬁcits observed in the limbic system of individuals with
DS with age. Combination therapy targeting several aspects,
or working upstream from the observed pathology, should
therefore be developed. Finally, a national registry for DSD
and age-matched control brain tissue and associated tissues
is long overdue. The development of such a repository
will allow centralized and streamlined studies into etiology
but also possible treatment paradigms for DSD and ﬁnally
render this ﬁeld well-deserved attention, using a nation-wide
collaboration for DSD-related studies.
Glossary
(i) Alzheimer’s disease (AD): the most common form of
dementia.
(ii) Down syndrome (DS): whole or segmental triplica-
tion of chromosome 21 in humans.
(iii) Basal Forebrain cholinergic neurons: small group of
neurons in basal forebrain carrying acetylcholine as
their transmitter, and innervating large portions of
the CNS.
(iv) Locus coeruleus noradrenergic neurons (LC-NE):
small population consisting of a few thousand
neurons in humans, located in the brainstem and
innervating most portions of the brain and spinal
cord.
(v) Amyloid beta: cleavage form of amyloid precursor
protein that accumulates in the brain of people
with AD and DSD and has both inﬂammatory and
oxidative stress eﬀects on neurons.
(vi) Proinﬂammatory cytokines: small molecules that are
released either in the blood or directly in the brain by
inﬂammatory cells and contribute to inﬂammatory
damage in the brain.
(vii) Oxidative stress scavengers: a set of enzymes, includ-
ing superoxide dismutates, catalase, and glutathione,
t h a tr e d u c ef r e er a d i c a l st ow a t e rv i aas e to f
enzymatic reactions.
(viii) Long-term potentiation (LTP): a form of cellular
potentiation of speciﬁc processes often used for
studiesofcellularlearningandmemorymechanisms.
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